IL152184A0 - Hydrophilic/lipophilic polymeric matrix dosage formulation - Google Patents

Hydrophilic/lipophilic polymeric matrix dosage formulation

Info

Publication number
IL152184A0
IL152184A0 IL15218401A IL15218401A IL152184A0 IL 152184 A0 IL152184 A0 IL 152184A0 IL 15218401 A IL15218401 A IL 15218401A IL 15218401 A IL15218401 A IL 15218401A IL 152184 A0 IL152184 A0 IL 152184A0
Authority
IL
Israel
Prior art keywords
hydrophilic
polymeric matrix
dosage formulation
matrix dosage
lipophilic polymeric
Prior art date
Application number
IL15218401A
Other languages
English (en)
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26332740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL152184(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IT2000MI000852A external-priority patent/IT1318470B1/it
Priority claimed from IT2000MI001963A external-priority patent/IT1318687B1/it
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of IL152184A0 publication Critical patent/IL152184A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
IL15218401A 2000-04-14 2001-04-12 Hydrophilic/lipophilic polymeric matrix dosage formulation IL152184A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2000MI000852A IT1318470B1 (it) 2000-04-14 2000-04-14 Matrici polimeriche idrofile/lipofile, in grado di cedere sostanzefarmacologiamente attive a velocita' predeterminata.
IT2000MI001963A IT1318687B1 (it) 2000-09-07 2000-09-07 Matrici polimeriche idrofile/lipofile, in grado di cedere sostanzefarmacologicamente attive a velocita' predeterminata.
PCT/GB2001/001726 WO2001078688A1 (en) 2000-04-14 2001-04-12 Hydrophilic/lipophilic polymeric matrix dosage formulation

Publications (1)

Publication Number Publication Date
IL152184A0 true IL152184A0 (en) 2003-05-29

Family

ID=26332740

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15218401A IL152184A0 (en) 2000-04-14 2001-04-12 Hydrophilic/lipophilic polymeric matrix dosage formulation
IL152184A IL152184A (en) 2000-04-14 2002-10-08 Multi-layered hydrophilic / lipophilic pill

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL152184A IL152184A (en) 2000-04-14 2002-10-08 Multi-layered hydrophilic / lipophilic pill

Country Status (24)

Country Link
US (4) US20030180359A1 (xx)
EP (4) EP1272167B1 (xx)
JP (2) JP5073907B2 (xx)
KR (4) KR101158968B1 (xx)
CN (1) CN1198598C (xx)
AR (1) AR030557A1 (xx)
AT (1) ATE401867T1 (xx)
AU (3) AU779623B2 (xx)
BR (1) BRPI0110038C1 (xx)
CA (1) CA2405508C (xx)
CZ (1) CZ303943B6 (xx)
DE (1) DE60134964D1 (xx)
DK (1) DK1272167T3 (xx)
ES (2) ES2580043T3 (xx)
HK (1) HK1053602A1 (xx)
HU (1) HU228269B1 (xx)
IL (2) IL152184A0 (xx)
MX (1) MXPA02010151A (xx)
NO (1) NO333572B1 (xx)
NZ (1) NZ521902A (xx)
PL (1) PL202689B1 (xx)
PT (1) PT1272167E (xx)
SI (1) SI1272167T1 (xx)
WO (1) WO2001078688A1 (xx)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US7130822B1 (en) * 2000-07-31 2006-10-31 Cognos Incorporated Budget planning
GB0125088D0 (en) * 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
ITMI20020514A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi
AU2004222339A1 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
EP1628642B2 (en) † 2003-05-14 2013-01-23 Aptalis Pharma Limited Controlled drug release composition resistant to in vivo mechanic stress
GB0319874D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Novel formulation
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2006079550A2 (en) 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
US20060078621A1 (en) * 2004-10-13 2006-04-13 Wedinger Robert S Method of providing customized drug delivery systems
DK1836665T3 (da) 2004-11-19 2013-04-15 Glaxosmithkline Llc Fremgangsmåde til specialtilpasset afgivelse af medikamentkombinationsprodukter med variabel dosis til individualisering af terapier
JP2008520726A (ja) * 2004-11-19 2008-06-19 スミスクライン・ビーチャム・コーポレイション 医薬製品
TWI274889B (en) * 2005-10-06 2007-03-01 Elan Microelectronics Corp Resistive touch screen measurement system
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
US20070185233A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20090238776A1 (en) * 2005-11-09 2009-09-24 Arif Ali Baig Oral Care Compositions and Methods
US20070129460A1 (en) * 2005-11-09 2007-06-07 Jayanth Rajaiah Denture adhesive articles
US7834066B2 (en) * 2005-11-09 2010-11-16 The Procter & Gamble Company Denture adhesive articles
US20070185237A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20070185236A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US20100317763A1 (en) * 2005-11-09 2010-12-16 Jayanth Rajaiah Denture Adhesive Articles
US20070185232A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20070185235A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
KR100816064B1 (ko) * 2006-08-16 2008-03-24 주식회사 케이티앤지 홍삼이 함유된 다중 정제 및 이의 제조방법
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
MX2009002235A (es) 2006-08-30 2009-03-13 Jagotec Ag Formulaciones de dosis oral, solidas, de liberacion controlada que comprenden nisoldipina.
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
WO2008085484A2 (en) * 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
GB0709541D0 (en) * 2007-05-17 2007-06-27 Jagotec Ag Pharmaceutical excipient
ES2692437T3 (es) 2007-08-13 2018-12-03 Abuse Deterrent Pharmaceutical Llc Fármacos resistentes al abuso, método de uso y método de preparación
KR101094231B1 (ko) * 2008-02-18 2011-12-14 하나제약 주식회사 서방성 고형 제제 및 그의 제조방법
WO2009149029A2 (en) * 2008-06-04 2009-12-10 The Procter & Gamble Company Denture adhesive compositions and methods
SI22849A (sl) * 2008-08-01 2010-02-26 Krka, Tovarna Zdravil, D.D., Novo Mesto Ropinirolni pripravek
WO2010015911A1 (en) * 2008-08-06 2010-02-11 Torrent Pharmaceuticals Limited Sustained release pharmaceutical compositions of ropinirole and process for preparation thereof
US20110195117A1 (en) * 2008-09-01 2011-08-11 Lupin Limited Controlled release compositions of ropinirole
ES2383149T3 (es) * 2008-09-04 2012-06-18 Bristol-Myers Squibb Company Composicion farmacéutica estable para la administración optimizada de un inhibidor de la unión del VIH
EP2163240A1 (en) 2008-09-12 2010-03-17 Universita' Degli Studi Di Genova A method for the production of bioadhesive compact matrices
EP2452677A1 (en) 2008-09-29 2012-05-16 Wockhardt Limited Extended release dosage form of ropinirole
WO2010044108A2 (en) 2008-10-17 2010-04-22 Rubicon Research Private Limited Controlled release formulations of ropinirole
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
US7927264B2 (en) * 2009-07-24 2011-04-19 Fitness Iq Llc Low-impact inertial exercise device
CN102470123B (zh) * 2009-09-19 2013-08-28 浙江华海药业股份有限公司 含有多巴胺受体激动剂的药物组合物
WO2011112709A1 (en) * 2010-03-09 2011-09-15 Elan Pharma International Limited Alcohol resistant enteric pharmaceutical compositions
BR112012022646A2 (pt) 2010-03-10 2016-08-23 Procter & Gamble composições adesivas para dentaduras
CA2801332C (en) 2010-10-15 2016-08-23 Straumann Holding Ag New emd formulation comprising pga
GR1007629B (el) 2011-07-13 2012-06-29 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα ελεγχομενης αποδεσμευσης ενος μη εργολινικου αγωνιστη της ντοπαμινης
CN104797267A (zh) 2012-06-26 2015-07-22 德玛医药 使用卫康醇、二乙酰二脱水卫矛醇、二溴卫矛醇或类似物或其衍生物治疗具有基因多型性或ahi1失调或突变患者的抗酪氨酸激酶抑制剂的恶性肿瘤的方法
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
WO2014146093A2 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US20150202302A1 (en) * 2014-01-22 2015-07-23 IVAX International GmbH Modified release formulations of pridopidine
KR20170015389A (ko) 2014-06-02 2017-02-08 테바 파마슈티컬 인더스트리즈 리미티드 확장 가능한 위체류 투여 형태
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
FR3026012B1 (fr) 2014-09-23 2017-12-01 Soc D'exploitation De Produits Pour Les Industries Chimiques Seppic Administration par voie orale d'au moins une substance active pharmaceutique et/ou antigenique
GB201504878D0 (en) 2015-03-23 2015-05-06 Algipharma As Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
CN110035718B (zh) 2016-12-02 2021-04-06 克雷西奥生物科技有限公司 胃内滞留系统
JP7147262B2 (ja) * 2017-05-23 2022-10-05 大正製薬株式会社 固形製剤
WO2019111132A1 (en) 2017-12-04 2019-06-13 Clexio Biosciences Ltd. Long acting gastric residence system
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
KR102536511B1 (ko) * 2020-06-25 2023-05-26 (주) 넥스팜코리아 날트렉손 서방형 매트릭스 제제와 부프로피온 서방형 매트릭스 제제의 단층정 복합제제와 그 제조 방법
JP7098008B2 (ja) * 2021-02-02 2022-07-08 ライオン株式会社 積層錠剤及びその製造方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4452808A (en) 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
US4574082A (en) 1983-07-29 1986-03-04 Revlon, Inc. One-phase silicone-based cosmetic products containing wax
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
IT1201136B (it) * 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
GB8714371D0 (en) 1987-06-19 1987-07-22 Smith Kline French Lab Process
US5032406A (en) 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
EP0384541A1 (en) 1989-02-24 1990-08-29 Gist-Brocades N.V. Long active food grade oxygen scavenger that can withstand pasteurization
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
JP2772695B2 (ja) 1990-01-26 1998-07-02 日水製薬株式会社 ３層錠
GB9008605D0 (en) 1990-04-17 1990-06-13 Smith Kline French Lab Process
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5190763A (en) 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
GB9015095D0 (en) 1990-07-09 1990-08-29 Smith Kline French Lab Therapeutic method
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
JPH04360826A (ja) 1991-06-07 1992-12-14 Bayer Yakuhin Kk 放出制御製剤
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5186818A (en) 1991-08-12 1993-02-16 Exxon Research And Engineering Company Catalytic processes
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5308729A (en) * 1992-04-30 1994-05-03 Lexmark International, Inc. Electrophotographic liquid developer with charge director
WO1993023035A2 (en) 1992-05-18 1993-11-25 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
DE59309771D1 (de) 1993-05-11 1999-10-14 Spirig Ag Festes bismut- und amoxycillinhaltiges Arzneipräparat und seine Verwendung
IT1265074B1 (it) * 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
IT1264517B1 (it) 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
US5387110A (en) 1993-11-12 1995-02-07 International Business Machines Corporation Reversible dual media adapter cable
IT1265240B1 (it) 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
US5395626A (en) * 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5645858A (en) * 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
GB9511366D0 (en) 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
IT1282576B1 (it) 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
DE19626045C2 (de) 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
SI0938318T1 (en) * 1996-08-29 2001-12-31 Sanofi Synthelabo Tablet with controlled release of alfuzosine chlorydrate
DE19640062B4 (de) * 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
IT1289160B1 (it) * 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
JP5170723B2 (ja) * 1997-01-10 2013-03-27 アボット・ラボラトリーズ 活性薬剤の制御放出用錠剤
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FR2766708B1 (fr) * 1997-07-30 2000-05-05 Galenix Dev Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
ATE277594T1 (de) 1998-06-03 2004-10-15 Alza Corp Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20030086972A1 (en) 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
JP4360826B2 (ja) 2003-04-24 2009-11-11 シャープ株式会社 半導体膜およびその製造方法

Also Published As

Publication number Publication date
AU2009230759A1 (en) 2009-11-19
AU779623C (en) 2001-10-30
US20110177167A1 (en) 2011-07-21
AU2005201805B2 (en) 2009-07-23
AU4857601A (en) 2001-10-30
CN1198598C (zh) 2005-04-27
JP5420207B2 (ja) 2014-02-19
KR20030023859A (ko) 2003-03-20
EP2343060A1 (en) 2011-07-13
DE60134964D1 (de) 2008-09-04
US7927624B2 (en) 2011-04-19
EP1272167A1 (en) 2003-01-08
CN1427717A (zh) 2003-07-02
EP1681051A1 (en) 2006-07-19
US20100003320A1 (en) 2010-01-07
KR100823392B1 (ko) 2008-04-17
AU2005201805A1 (en) 2005-05-26
BRPI0110038B1 (pt) 2019-02-19
KR20090094406A (ko) 2009-09-04
HUP0300530A2 (hu) 2003-09-29
ES2580043T3 (es) 2016-08-18
US8460706B2 (en) 2013-06-11
BRPI0110038C1 (pt) 2021-05-25
AR030557A1 (es) 2003-08-27
BRPI0110038B8 (pt) 2019-07-16
EP3175848A1 (en) 2017-06-07
MXPA02010151A (es) 2003-09-10
KR101158968B1 (ko) 2012-06-21
DK1272167T3 (da) 2008-09-08
US8303986B2 (en) 2012-11-06
KR20080047630A (ko) 2008-05-29
JP2003530423A (ja) 2003-10-14
CZ303943B6 (cs) 2013-07-10
AU779623B2 (en) 2005-02-03
ATE401867T1 (de) 2008-08-15
BR0110038A (pt) 2002-12-31
EP1681051B1 (en) 2016-04-06
NO20024919D0 (no) 2002-10-11
CZ20023415A3 (cs) 2003-05-14
PL365837A1 (en) 2005-01-10
CA2405508A1 (en) 2001-10-25
NZ521902A (en) 2004-03-26
HU228269B1 (en) 2013-02-28
IL152184A (en) 2009-08-03
PL202689B1 (pl) 2009-07-31
PT1272167E (pt) 2008-08-12
CA2405508C (en) 2011-02-01
SI1272167T1 (sl) 2008-12-31
US20070264336A1 (en) 2007-11-15
ES2307608T3 (es) 2008-12-01
KR20070065922A (ko) 2007-06-25
EP1272167B1 (en) 2008-07-23
NO333572B1 (no) 2013-07-08
JP2009029813A (ja) 2009-02-12
HK1053602A1 (en) 2003-10-31
NO20024919L (no) 2002-12-06
WO2001078688A1 (en) 2001-10-25
US20030180359A1 (en) 2003-09-25
JP5073907B2 (ja) 2012-11-14
HUP0300530A3 (en) 2006-07-28

Similar Documents

Publication Publication Date Title
HUP0300530A3 (en) Hydrophilic/lipophilic polymeric matrix dosage formulation
HUP0400566A3 (en) Pharmaceutical preparation comprising an active dispersed on a matrix
EG23943A (en) Flash-melt oral dosage formulation
IL154012A0 (en) Hydrogel-driven drug dosage form
GB0104786D0 (en) Active Matrix Device
AU2002232492A1 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
GB0014074D0 (en) Active matrix array devices
HUP0301177A3 (en) Ion-strength independent sustained release pharmaceutical formulation
GB0031039D0 (en) Active matrix devices
AUPQ761100A0 (en) Lipophilic medicament
GB9909154D0 (en) Pharmaceutical formulation
GB0014851D0 (en) Novel pharmaceutical formulation
GB9926251D0 (en) Pharmaceutical formulation
GB0014883D0 (en) Novel pharmaceutical formulation
GB0014892D0 (en) Novel pharmaceutical formulation
GB0014947D0 (en) Novel pharmaceutical formulation
GB0020999D0 (en) Active matrix display device
EP1414417A4 (en) PHARMACEUTICAL FORMULATION
GB0019084D0 (en) Pharmaceutical formulation
GB0018686D0 (en) Pharmaceutical formulation
GB0018654D0 (en) Pharmaceutical formulation
GB0014424D0 (en) Pharmaceutical formulation
GB0014451D0 (en) Pharmaceutical formulation
GB0014869D0 (en) Novel pharmaceutical formulation
AU2001258044A1 (en) Lipophilic medicament